CHANDIGARH, India, March 6 /PRNewswire/ -- InnoCentive today announced that its annual conference was held at the Indian government's National Institute for Pharmaceutical Education and Research (NIPER), in Chandigarh, Punjab, on Saturday, March 4, 2006. This year's event theme was, "InnoCentive Innovation Series: Value Addition to Natural Products." Five prominent speakers from prestigious Indian universities and institutes addressed the conference that was attended by scientists, students and research firms from across the country. (Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060306/SFM094 http://www.newscom.com/cgi-bin/prnh/20050919/SFM013 ) Commenting on the successful event, Ali Hussein, InnoCentive's chief marketing officer, vice president of global markets, said, "Having India's prestigious National Institute for Pharmaceutical Education and Research agree to host this year's conference was a clear statement of the importance that the Indian pharmaceutical industry places on innovation and global collaboration, both hallmarks of InnoCentive's business model." Hussein added, "We were also delighted to have the strong support and active participation by some of India's leading scholars in the pharmaceutical field, who shared their knowledge on R&D issues affecting India's pharmaceutical industry. Hussein addressed the conference along with Dr. P. Ramarao, Professor, Director, NIPER; Dr. Bijoy Kundu, deputy director, Division of Medicinal Chemistry, Central Drug Research Institute, Lucknow; Dr. Virinder S. Parmar, professor, Department of Chemistry, University of Delhi; Dr. G.N. Qazi, director, Regional Research Laboratory, Jammu; Dr. Mukund K. Gurjar, deputy director, Division of Organic Chemistry: Technology at the National Chemical Laboratory, Pune; and Dr. K.K. Bhutani, dean, NIPER's Department of Natural Products. Declared an "Institute of National Importance" by the Indian government, NIPER is located in the city of Chandigarh in India's Punjab province, and was established as a center for advanced studies and research for the pharmaceutical sciences. NIPER operates under the aegis of the Ministry of Chemicals and Fertilizers. The institute provides leadership for the pharmaceutical sciences and related areas not only within India, but also to countries in South East Asia, South Asia and Africa. InnoCentive offers companies an opportunity to increase their R&D potential by posting challenges to a confidential online forum and gaining access to leading scientific minds. InnoCentive has developed a solid global brand with their unique virtual R&D network of over 90,000 scientists spanning more than 175 countries that has greatly helped companies reduce the escalating costs and shorten the time required to bring products to market. InnoCentive's goal is to further advance scientific research and collaboration in worldwide markets. About InnoCentive InnoCentive is the first online forum that allows world-class scientists and science-based companies to collaborate in a global scientific community to achieve innovative solutions to complex challenges. Companies including Boeing, Eli Lilly and Company, Procter & Gamble and others, which collectively spend billions of dollars on R&D, post scientific problems confidentially on the InnoCentive Web site where more than 90,000 scientists and scientific organizations in more than 175 countries can solve them. Scientists who deliver solutions that best meet InnoCentive's challenge requirements receive financial awards ranging up to and over $100,000. To learn more and to register as an InnoCentive Solver, visit the InnoCentive Web site at www.innocentive.com. NOTE: InnoCentive and InnoCentive Challenge are registered trademarks of InnoCentive, Inc. Other product or service names mentioned herein are the trademarks of their respective owners. Contact: Ali Hussein, Chief Marketing Officer, Vice President of Global Markets of InnoCentive, +1-978-482-3366; or Micky Huang, +1-510-226-6780, ext. 154, or firstname.lastname@example.org, for InnoCentive.
SOURCE InnoCentive, Inc.